[EN] COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS<br/>[FR] AGENTS PHARMACEUTIQUES EN COMBINAISON EN TANT QU'INHIBITEURS DE RSV
申请人:ENANTA PHARM INC
公开号:WO2019067864A1
公开(公告)日:2019-04-04
The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.
[EN] BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS<br/>[FR] DÉRIVÉS BENZODIAZÉPINE UTILISÉS COMME INHIBITEURS DU VIRUS RESPIRATOIRE SYNCYTIAL (RSV)
申请人:ENANTA PHARM INC
公开号:WO2017015449A1
公开(公告)日:2017-01-26
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Copper‐Catalyzed Selective N‐Arylation of Oxadiazolones by Diaryliodonium Salts
作者:Natalia S. Soldatova、Artem V. Semenov、Kirill K. Geyl、Sergey V. Baykov、Anton A. Shetnev、Anna S. Konstantinova、Mikhail M. Korsakov、Mekhman S. Yusubov、Pavel S. Postnikov
DOI:10.1002/adsc.202100426
日期:2021.7.20
Here, we report the method for copper-catalyzed N-arylation of diverse oxadiazolones by diaryliodoniumsalts under mild conditions in high yields (up to 92%) using available CuI as a catalyst. The developed method allows utilizing both symmetric and unsymmetric diaryliodoniumsalts bearing auxiliary groups such as 2,4,6-trimethoxyphenyl (TMP). We found that the steric effects in aryl moieties determined
在这里,我们报告了使用可用的 CuI 作为催化剂在温和条件下以高产率(高达 92%)通过二芳基碘盐对不同恶二唑酮进行铜催化 N-芳基化的方法。所开发的方法允许使用带有辅助基团(例如 2,4,6-三甲氧基苯基 (TMP))的对称和不对称二芳基碘盐。我们发现芳基部分的空间效应决定了 1,2,4-oxadiazol-5(4 H )-ones的 N-和 O-芳基化的化学选择性。甲基取代的二芳基碘盐显示出作为选择性芳基化试剂的巨大潜力。结构研究表明 1,2,4-oxadiazol-5(4 H)-对空间位阻二芳基碘鎓盐的芳基化的影响。还证明了所提出方法的合成应用对 1,3,4-恶二唑-2(3 H )-酮和 1,2,4-恶二唑-5-硫醇的选择性芳基化。
Synthesis of 5-substituted-3H-[1,3,4]-oxadiazol-2-one derivatives: a carbon dioxide route (CDR)
作者:M. Brahmayya、Shenghong A. Dai、S.-Y. Suen
DOI:10.1039/c5ra08910g
日期:——
Access to a series of 5-substituted-3(H)-1,3,4-oxadiazole-2-one derivatives is described directly using the greenhouse gas CO2.
描述了直接使用温室气体CO₂获得一系列5-取代-3(H)-1,3,4-噁二唑-2-酮衍生物的访问。
Palladium-Catalyzed Oxidative O–H/N–H Carbonylation of Hydrazides: Access to Substituted 1,3,4-Oxadiazole-2(3<i>H</i>)-ones
cyclocarbonylation provides an efficient and direct approach for the construction of valuable 1,3,4-oxadiazole-2(3H)-ones and their derivatives. The reaction also facilitated the convenient synthesis of BMS-191011, an opener of the cloned large-conductance Ca2+-activated potassiumchannel, providing an attractive method for medicinal chemistry.